PMID- 15887830
OWN - NLM
STAT- MEDLINE
DCOM- 20050627
LR  - 20171116
IS  - 0019-5847 (Print)
IS  - 0019-5847 (Linking)
VI  - 102
IP  - 10
DP  - 2004 Oct
TI  - Reviparin sodium clivarine: a review of its therapeutic use.
PG  - 589-90, 592
AB  - Reviparin sodium (clivarine) is a second generation LMWH, developed with the aim 
      of maximising the antithrombotic action while minimising the risk of haemorrhage. 
      Clivarine has been extensively studied in acute coronary syndrome. Various 
      clinical studies in unstable angina and acute coronary syndrome have proved that 
      clivarine in a dosage of 3436anti-Xa units twice daily is an effective 
      antithrombotic agent. Clivarine has been shown to be as effective as 
      unfractionated heparin (UFH) in thromboprophylaxis and it has less incidence of 
      local haematoma at injection site. At a daily dose of 1432 IU anti-Xa it was 
      found to be as effective as UFH in preventing deep vein thrombosis (DVT) in 
      moderate risk surgery (general and abdominal) and reducing to a significant 
      extent DVT in patients with brace immobilisation of the legs. At a daily dose of 
      3436 IU anti-Xa reviparin was as effective as UFH or enoxaparin in preventing DVT 
      in high risk orthopaedic surgery and as effective as UFH in prevention of DVT 
      and/or pulmonary embolism (PE) and/or mortality in high risk orthopaedic surgery. 
      In patients with acute venous thrombo-embolism (VTE), reviparin was more 
      effective than UFH in thrombus reduction and at least as effective as UFH in the 
      prevention of clinical recurrence of DVT and/or PE. The use of reviparin is 
      associated with a similar or lower incidence of bleeding complications than UFH. 
      The benefits of reviparin sodium have been demonstrated in a number of clinical 
      trials.
FAU - Gore, Madhuri
AU  - Gore M
AD  - Department of Surgery, LTM Medical College and General Hospital, Mumbai 400 022.
FAU - Kelkar, Prafulla
AU  - Kelkar P
FAU - Rege, Nirmala
AU  - Rege N
FAU - Ross, Cecil
AU  - Ross C
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Indian Med Assoc
JT  - Journal of the Indian Medical Association
JID - 7505608
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5R0L1D739E (reviparin)
SB  - IM
MH  - Anticoagulants/administration & dosage/therapeutic use
MH  - Coronary Disease/drug therapy
MH  - Coronary Restenosis/prevention & control
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Myocardial Infarction/*drug therapy
MH  - Thromboembolism/prevention & control
MH  - Venous Thrombosis/prevention & control
RF  - 23
EDAT- 2005/05/13 09:00
MHDA- 2005/06/28 09:00
CRDT- 2005/05/13 09:00
PHST- 2005/05/13 09:00 [pubmed]
PHST- 2005/06/28 09:00 [medline]
PHST- 2005/05/13 09:00 [entrez]
PST - ppublish
SO  - J Indian Med Assoc. 2004 Oct;102(10):589-90, 592.